Hypertensive nephropathy primary prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Hypertensive nephropathy}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References==..." |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hypertensive nephropathy}} | {{Hypertensive nephropathy}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{CMG}} {{AE}}{{NN}} | |||
==Overview== | |||
Effective measures for primary prevention of [[Hypertensive nephropathy]] include detecting and controlling [[hypertension]] at the initial stages. | |||
==Primary Prevention== | |||
*Effective measures for reducing blood pressure as primary prevention of [[Hypertensive nephropathy]] include:<ref name="HartBakris2010">{{cite journal|last1=Hart|first1=Peter D|last2=Bakris|first2=George L|title=Hypertensive nephropathy: prevention and treatment recommendations|journal=Expert Opinion on Pharmacotherapy|volume=11|issue=16|year=2010|pages=2675–2686|issn=1465-6566|doi=10.1517/14656566.2010.485612}}</ref> | |||
**'''Lifestyle modification''' | |||
***Weight reduction | |||
***[[DASH]] diet | |||
***[[sodium]] intake restriction | |||
***Increase physical activity | |||
**'''Pharmacological therapy for [[hypertension]]''' | |||
***Among medications for controlling BP, Renin-angiotensin-aldosterone (RAAS) blockers such as [[ACEI]] or [[ARB]] play a significant role in preventing progression to [[ESRD]] by reducing [[proteinuria]] in hypertensive patients. | |||
****According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and [[CKD]] regardless of [[proteinuria]].<ref name="WheltonCarey2018">{{cite journal|last1=Whelton|first1=Paul K.|last2=Carey|first2=Robert M.|last3=Aronow|first3=Wilbert S.|last4=Casey|first4=Donald E.|last5=Collins|first5=Karen J.|last6=Dennison Himmelfarb|first6=Cheryl|last7=DePalma|first7=Sondra M.|last8=Gidding|first8=Samuel|last9=Jamerson|first9=Kenneth A.|last10=Jones|first10=Daniel W.|last11=MacLaughlin|first11=Eric J.|last12=Muntner|first12=Paul|last13=Ovbiagele|first13=Bruce|last14=Smith|first14=Sidney C.|last15=Spencer|first15=Crystal C.|last16=Stafford|first16=Randall S.|last17=Taler|first17=Sandra J.|last18=Thomas|first18=Randal J.|last19=Williams|first19=Kim A.|last20=Williamson|first20=Jeff D.|last21=Wright|first21=Jackson T.|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults|journal=Journal of the American College of Cardiology|volume=71|issue=19|year=2018|pages=e127–e248|issn=07351097|doi=10.1016/j.jacc.2017.11.006}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 11: | Line 34: | ||
[[Category:Kidney diseases]] | [[Category:Kidney diseases]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Nephrology]] | |||
Latest revision as of 21:04, 18 June 2020
|
Hypertensive nephropathy Microchapters |
|
Differentiating Hypertensive Nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertensive nephropathy primary prevention On the Web |
|
American Roentgen Ray Society Images of Hypertensive nephropathy primary prevention |
|
Risk calculators and risk factors for Hypertensive nephropathy primary prevention |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]
Overview
Effective measures for primary prevention of Hypertensive nephropathy include detecting and controlling hypertension at the initial stages.
Primary Prevention
- Effective measures for reducing blood pressure as primary prevention of Hypertensive nephropathy include:[1]
- Lifestyle modification
- Pharmacological therapy for hypertension
- Among medications for controlling BP, Renin-angiotensin-aldosterone (RAAS) blockers such as ACEI or ARB play a significant role in preventing progression to ESRD by reducing proteinuria in hypertensive patients.
- According to 2017 guidelines, the goal of BP is < 130/80 mmHg for patients with hypertension and CKD regardless of proteinuria.[2]
- Among medications for controlling BP, Renin-angiotensin-aldosterone (RAAS) blockers such as ACEI or ARB play a significant role in preventing progression to ESRD by reducing proteinuria in hypertensive patients.
References
- ↑ Hart, Peter D; Bakris, George L (2010). "Hypertensive nephropathy: prevention and treatment recommendations". Expert Opinion on Pharmacotherapy. 11 (16): 2675–2686. doi:10.1517/14656566.2010.485612. ISSN 1465-6566.
- ↑ Whelton, Paul K.; Carey, Robert M.; Aronow, Wilbert S.; Casey, Donald E.; Collins, Karen J.; Dennison Himmelfarb, Cheryl; DePalma, Sondra M.; Gidding, Samuel; Jamerson, Kenneth A.; Jones, Daniel W.; MacLaughlin, Eric J.; Muntner, Paul; Ovbiagele, Bruce; Smith, Sidney C.; Spencer, Crystal C.; Stafford, Randall S.; Taler, Sandra J.; Thomas, Randal J.; Williams, Kim A.; Williamson, Jeff D.; Wright, Jackson T. (2018). "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". Journal of the American College of Cardiology. 71 (19): e127–e248. doi:10.1016/j.jacc.2017.11.006. ISSN 0735-1097.